RxSight, Inc.(RXST) Stock Research - Grey Stern Research

RxSight, Inc. (RXST) Stock Analysis

$31.32 (4.12%)

RXST Financial Performance


Use the table below to view RxSight, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $31.32 -
52 Week Low $26.29 -
52 Week High $66.54 -
Market Cap $1.3 Billion 1/17
Gross Margin 56% 13/17
Profit Margin -14% 5/17
EBITDA margin -20% 9/17
Q3 - 2024 Revenue $45.4 Million 6/17
Q3 - 2024 Earnings -$6.3 Million 6/17
Q3 - 2024 Free Cash Flow -$373,000 Million 7/17
Trailing 4 Quarters Revenue $147.2 Million 8/17
Trailing 4 Quarters Earnings -$30.7 Million 7/17
Quarterly Earnings Growth 49% 3/17
Annual Earnings Growth 43% 1/17
Quarterly Revenue Growth 48% 1/17
Annual Revenue Growth 58% 1/17
Cash On Hand $16.7 Million 13/17
Short Term Debt $734,000 9/17
Long Term Debt $10.6 Million 15/17

RxSight, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare RxSight, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 2/17
PS 8.57 4/17
PB 4.55 8/17
PC 75.50 1/17
Liabilities to Equity 0.12 16/17
ROA -0.10 5/17
ROE -0.11 5/17
Current Ratio 9.35 1/17
Quick Ratio 7.14 1/17
Long Term Debt to Equity 0.04 15/17
Debt to Equity 0.04 15/17
Burn Rate 2.41 10/17
Cash to Cap 0.01 17/17
CCR 0.06 11/17
EV to EBITDA -136.24 16/17
EV to Revenue 8.54 2/17

Company Details

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

CEO:

Website: https://www.rxsight.com

Address: 100 Columbia Aliso Viejo, CA

Exchange: NASDAQ Global Market

Industry: Medical Devices

RxSight, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to RxSight, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
AxoGen, Inc. AXGN $824.3 Million
Varex Imaging Corporation VREX $558.7 Million
Orthofix Medical Inc. OFIX $685.6 Million
OrthoPediatrics Corp. KIDS $631.6 Million
IRadimed Corporation IRMD $744.9 Million
STRATA Skin Sciences, Inc. SSKN $12.4 Million
Vapotherm, Inc. VAPO $13.6 Million
Apyx Medical Corporation APYX $53.5 Million
SI-BONE, Inc. SIBN $690.7 Million
Pulmonx Corporation LUNG $265.4 Million
Talis Biomedical Corporation TLIS $2.8 Million
NeuroPace, Inc. NPCE $358.2 Million
Treace Medical Concepts, Inc. TMCI $527.7 Million
Sight Sciences, Inc. SGHT $157.8 Million
CVRx, Inc. CVRX $412.5 Million
Paragon 28, Inc. FNA $858.1 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
RXST Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 45.4 Million -$6.3 Million
Q2 2024 $ 34.9 Million -$6.1 Million
Q1 2024 $ 38.3 Million -$9.1 Million
Q4 2023 $ 28.6 Million -$9.2 Million
Q3 2023 $ 30.7 Million -$12.4 Million
Q2 2023 $ 20.8 Million -$13.8 Million
Q1 2023 $ 17.5 Million -$14.8 Million
Q4 2022 $ 16.1 Million -$15.6 Million

View All

RXST Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $16.7 Million $310.5 Million $11.3 Million $277.3 Million
Q2 2024 $24.4 Million $305.5 Million $11.4 Million $275.2 Million
Q1 2024 $32.6 Million $183.2 Million $2.5 Million $163.9 Million
Q4 2023 $9.7 Million $182.6 Million $3.0 Million $160.4 Million
Q3 2023 $9.9 Million $181.9 Million $3.3 Million $161.5 Million
Q2 2023 $8.8 Million $195.3 Million $23.4 Million $157.2 Million
Q1 2023 $11.0 Million $202.5 Million $44.6 Million $145.0 Million
Q4 2022 $11.8 Million $150.2 Million $45.0 Million $89.9 Million

View All

RXST Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$373,000 -$1.1 Million -$7.0 Million
Q2 2024 -$5.6 Million -$1.5 Million -$8.2 Million
Q1 2024 -$11.3 Million -$2.0 Million $23.0 Million
Q4 2023 -$11.5 Million -$1.6 Million -$167,000
Q3 2023 -$8.6 Million -$653,000 $1.1 Million
Q2 2023 -$9.4 Million -$1.8 Million -$2.3 Million
Q1 2023 -$18.5 Million -$747,000 -$822,000
Q4 2022 -$14.2 Million -$362,000 $2.9 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions